OIM
RPRX

Oracle Investment Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Oracle Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,014,164
Closed -$10M – 32
2014
Q3 		$10M Sell
1,014,164
-252,962
-20% -$3.75M 1.39% 18
2014
Q2 		$21.9M Buy
1,267,126
+24,800
+2% +$404K 2.66% 13
2014
Q1 		$22M Buy
+1,242,326
New +$24M 2.52% 13

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oracle Investment Management's RPRX Position: Q4 2014 in Review

Oracle Investment Management sold out of Repros Therapeutics Inc. (RPRX) in Q4 2014, closing a stake of 1,014,164 shares — an estimated $10M sold.

Oracle Investment Management first reported a position in RPRX in Q1 2014 and held it in 3 quarters. The position peaked at $22M in Q1 2014. 80 funds tracked by Wall St. Rank hold RPRX as of Q4 2014.

  • Oracle Investment Management reported no remaining Repros Therapeutics Inc. position as of Q4 2014 after selling out during the quarter.
  • Oracle Investment Management sold 1,014,164 Repros Therapeutics Inc. shares in Q4 2014, an estimated $10M.
  • Oracle Investment Management first reported a position in Repros Therapeutics Inc. in Q1 2014 and held it in 3 quarters.
  • Oracle Investment Management's Repros Therapeutics Inc. position peaked at $22M in Q1 2014.
  • 80 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2014.

Based on Oracle Investment Management's 13F filing for Q4 2014, filed 17 Feb 2015.